NCT03977805

Metabolism and Disposition of [14C] Herombopag in Chinese Healthy Human Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Jiangsu HengRui Medicine Co., Ltd. · Industry
• Sex: Male
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

This study is a single-center, open-label, single-dose design. It is planning to enroll six Chinese healthy adult male subjects. The metabolism and disposition of Herombopag, will be studied in these subjects after a single oral administration of a solution dose of \[14C\] Herombopag (5 mg, 100 uCi).

Detailed description

The metabolism and disposition of Herombopag, will be studied in six healthy men after a single oral administration of a solution dose of \[14C\]eltrombopag (5 mg,100 uCi). The sutdy will investigate total radioactivity pharmacokinetics in whole blood and plasma 、quantitatively analyze the the total radioactivity in the excreta、evaluate the predominant route of elimination and indentify the Metabolite profiles in plasma 、urine and faces.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Hetrombopag Olamine	a single oral taking

Timeline

• Start date: 2019-05-25
• Primary completion: 2019-06-13
• Completion: 2019-06-13
• First posted: 2019-06-06
• Last updated: 2020-05-08

Locations

1 site across 1 country: China